Linked Life Data

2496708

Source:http://linkedlifedata.com/resource/pubmed/id/2496708

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1989-6-16
pubmed:abstractText
Recombinant human interferon beta (rIFN-beta) reduces replication of HIV in cultured peripheral mononuclear cells. The effect is most pronounced when high levels of the drug are employed. Maintenance of the rIFN-beta in culture is required since removal of the agent generally leads to a return of virus production by the infected cells. Moreover, at low concentrations of the drug, a breakthrough in HIV replication is observed. High concentrations of the rIFN-beta (greater than 100 units/ml) were cytotoxic for transformed T cells. This latter observations suggests that rIFN-beta might be useful in human T-cell malignancies. Beta interferon therefore might be useful for the treatment of HIV infection, particularly since side effects of the drug are limited in treated individuals.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0269-9370
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-31
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
HIV replication can be blocked by recombinant human interferon beta.
pubmed:affiliation
Cancer Research Institute, University of California, School of Medicine, San Francisco 94143.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't